FTRE

$9.60+0.33 (+3.56%)

Market OpenAs of Mar 17, 7:05 PM UTC

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$9.60
Potential Upside
5%
Whystock Fair Value$10.08
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as cl...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$897.60M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.78
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-102.41%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.87

Recent News

StockStory
Mar 17, 2026

Fortrea, Alignment Healthcare, PacBio, DexCom, and Humana Stocks Trade Up, What You Need To Know

A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
StockStory
Mar 12, 2026

3 Small-Cap Stocks with Open Questions

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 9, 2026

How The Fortrea (FTRE) Story Is Shifting As Analysts Split On Future Upside

Fortrea Holdings now carries a refreshed fair value estimate of US$14.44, down from US$16.44, reflecting updated assumptions behind the stock’s price target. This reset sits against a mixed backdrop on the Street, where some analysts are lifting ratings and targets into the low to mid US$20s while others are trimming their expectations into the low to mid teens. As you read on, you will see how these shifting targets and views can help you track the evolving narrative around Fortrea and what...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 9, 2026

3 Stocks Under $50 Walking a Fine Line

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 6, 2026

Option Care Health, CooperCompanies, Neogen, GoodRx, and Fortrea Shares Are Falling, What You Need To Know

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.